Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1996 Feb;40(2):413–418. doi: 10.1128/aac.40.2.413

The guanine nucleoside analog penciclovir is active against chronic duck hepatitis B virus infection in vivo.

E Lin 1, C Luscombe 1, Y Y Wang 1, T Shaw 1, S Locarnini 1
PMCID: PMC163125  PMID: 8834889

Abstract

Ducks congenitally infected with duck hepatitis B virus (HBV) were treated with the antiviral guanine nucleoside analog penciclovir for 4 weeks at a dose of 10 mg/kg of body weight per day. The effects of treatment on viremia and intrahepatic viral genome replication, transcription, and translation were examined. In seven of eight penciclovir-treated ducks, viremia was barely detectable after a week of treatment. After 4 weeks of treatment, molecular hybridization studies showed that intrahepatic viral DNA, RNA, and protein levels were significantly reduced compared with those in placebo-treated controls. Synthesis of all viral replicative intermediates, including the normally persistent viral supercoiled DNA species, was inhibited by penciclovir treatment. Examination of liver tissue sections after in situ DNA hybridization or immunohistochemical staining confirmed that viral DNA and protein synthesis had been profoundly inhibited in most hepatic parenchymal cells. However, small subpopulations of cells, in particular the small bile duct epithelial cells, remained strongly positive for duck HBV antigens and DNA despite treatment. There was no evidence of toxicity associated with penciclovir therapy. This study confirms the safety and potent antihepadnaviral activity of penciclovir in vivo but indicates that further improvements in antiviral therapy will be required to completely eliminate HBV infection.

Full Text

The Full Text of this article is available as a PDF (633.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bishop N., Civitico G., Wang Y. Y., Guo K. J., Birch C., Gust I., Locarnini S. Antiviral strategies in chronic hepatitis B virus infection: I. Establishment of an in vitro system using the duck hepatitis B virus model. J Med Virol. 1990 Jun;31(2):82–89. doi: 10.1002/jmv.1890310204. [DOI] [PubMed] [Google Scholar]
  2. Civitico G. M., Locarnini S. A. The half-life of duck hepatitis B virus supercoiled DNA in congenitally infected primary hepatocyte cultures. Virology. 1994 Aug 15;203(1):81–89. doi: 10.1006/viro.1994.1457. [DOI] [PubMed] [Google Scholar]
  3. Dean J., Bowden S., Locarnini S. Reversion of duck hepatitis B virus DNA replication in vivo following cessation of treatment with the nucleoside analogue ganciclovir. Antiviral Res. 1995 May;27(1-2):171–178. doi: 10.1016/0166-3542(94)00081-i. [DOI] [PubMed] [Google Scholar]
  4. Fourel I., Saputelli J., Schaffer P., Mason W. S. The carbocyclic analog of 2'-deoxyguanosine induces a prolonged inhibition of duck hepatitis B virus DNA synthesis in primary hepatocyte cultures and in the liver. J Virol. 1994 Feb;68(2):1059–1065. doi: 10.1128/jvi.68.2.1059-1065.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Guo K. J., Bowden D. S. Digoxigenin-labeled probes for the detection of hepatitis B virus DNA in serum. J Clin Microbiol. 1991 Mar;29(3):506–509. doi: 10.1128/jcm.29.3.506-509.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Ilsley D. D., Lee S. H., Miller W. H., Kuchta R. D. Acyclic guanosine analogs inhibit DNA polymerases alpha, delta, and epsilon with very different potencies and have unique mechanisms of action. Biochemistry. 1995 Feb 28;34(8):2504–2510. doi: 10.1021/bi00008a014. [DOI] [PubMed] [Google Scholar]
  7. Jilbert A. R., Freiman J. S., Burrell C. J., Holmes M., Gowans E. J., Rowland R., Hall P., Cossart Y. E. Virus-liver cell interactions in duck hepatitis B virus infection. A study of virus dissemination within the liver. Gastroenterology. 1988 Nov;95(5):1375–1382. doi: 10.1016/0016-5085(88)90375-7. [DOI] [PubMed] [Google Scholar]
  8. Keller P. M., McKee S. A., Fyfe J. A. Cytoplasmic 5'-nucleotidase catalyzes acyclovir phosphorylation. J Biol Chem. 1985 Jul 25;260(15):8664–8667. [PubMed] [Google Scholar]
  9. Lee B., Luo W. X., Suzuki S., Robins M. J., Tyrrell D. L. In vitro and in vivo comparison of the abilities of purine and pyrimidine 2',3'-dideoxynucleosides to inhibit duck hepadnavirus. Antimicrob Agents Chemother. 1989 Mar;33(3):336–339. doi: 10.1128/aac.33.3.336. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Lenhoff R. J., Summers J. Construction of avian hepadnavirus variants with enhanced replication and cytopathicity in primary hepatocytes. J Virol. 1994 Sep;68(9):5706–5713. doi: 10.1128/jvi.68.9.5706-5713.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Lenhoff R. J., Summers J. Coordinate regulation of replication and virus assembly by the large envelope protein of an avian hepadnavirus. J Virol. 1994 Jul;68(7):4565–4571. doi: 10.1128/jvi.68.7.4565-4571.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Littler E., Stuart A. D., Chee M. S. Human cytomegalovirus UL97 open reading frame encodes a protein that phosphorylates the antiviral nucleoside analogue ganciclovir. Nature. 1992 Jul 9;358(6382):160–162. doi: 10.1038/358160a0. [DOI] [PubMed] [Google Scholar]
  13. Lok A. S. Treatment of chronic hepatitis B. J Viral Hepat. 1994;1(2):105–124. doi: 10.1111/j.1365-2893.1994.tb00110.x. [DOI] [PubMed] [Google Scholar]
  14. Luscombe C., Pedersen J., Bowden S., Locarnini S. Alterations in intrahepatic expression of duck hepatitis B viral markers with ganciclovir chemotherapy. Liver. 1994 Aug;14(4):182–192. doi: 10.1111/j.1600-0676.1994.tb00072.x. [DOI] [PubMed] [Google Scholar]
  15. Mason W. S., Cullen J., Saputelli J., Wu T. T., Liu C., London W. T., Lustbader E., Schaffer P., O'Connell A. P., Fourel I. Characterization of the antiviral effects of 2' carbodeoxyguanosine in ducks chronically infected with duck hepatitis B virus. Hepatology. 1994 Feb;19(2):398–411. [PubMed] [Google Scholar]
  16. Mason W. S., Halpern M. S., England J. M., Seal G., Egan J., Coates L., Aldrich C., Summers J. Experimental transmission of duck hepatitis B virus. Virology. 1983 Dec;131(2):375–384. doi: 10.1016/0042-6822(83)90505-6. [DOI] [PubMed] [Google Scholar]
  17. Mason W. S., Seal G., Summers J. Virus of Pekin ducks with structural and biological relatedness to human hepatitis B virus. J Virol. 1980 Dec;36(3):829–836. doi: 10.1128/jvi.36.3.829-836.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Newbold J. E., Xin H., Tencza M., Sherman G., Dean J., Bowden S., Locarnini S. The covalently closed duplex form of the hepadnavirus genome exists in situ as a heterogeneous population of viral minichromosomes. J Virol. 1995 Jun;69(6):3350–3357. doi: 10.1128/jvi.69.6.3350-3357.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Niu J., Wang Y., Dixon R., Bowden S., Qiao M., Einck L., Locarnini S. The use of ampligen alone and in combination with ganciclovir and coumermycin A1 for the treatment of ducks congenitally-infected with duck hepatitis B virus. Antiviral Res. 1993 Jun;21(2):155–171. doi: 10.1016/0166-3542(93)90051-j. [DOI] [PubMed] [Google Scholar]
  20. Price P. M., Banerjee R., Jeffrey A. M., Acs G. The mechanism of inhibition of hepatitis B virus replication by the carbocyclic analog of 2'-deoxyguanosine. Hepatology. 1992 Jul;16(1):8–12. doi: 10.1002/hep.1840160103. [DOI] [PubMed] [Google Scholar]
  21. Saltzman R., Jurewicz R., Boon R. Safety of famciclovir in patients with herpes zoster and genital herpes. Antimicrob Agents Chemother. 1994 Oct;38(10):2454–2457. doi: 10.1128/aac.38.10.2454. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Shaw T., Amor P., Civitico G., Boyd M., Locarnini S. In vitro antiviral activity of penciclovir, a novel purine nucleoside, against duck hepatitis B virus. Antimicrob Agents Chemother. 1994 Apr;38(4):719–723. doi: 10.1128/aac.38.4.719. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Shaw T., Locarnini S. A. Hepatic purine and pyrimidine metabolism: implications for antiviral chemotherapy of viral hepatitis. Liver. 1995 Aug;15(4):169–184. doi: 10.1111/j.1600-0676.1995.tb00667.x. [DOI] [PubMed] [Google Scholar]
  24. Sherker A. H., Marion P. L. Hepadnaviruses and hepatocellular carcinoma. Annu Rev Microbiol. 1991;45:475–507. doi: 10.1146/annurev.mi.45.100191.002355. [DOI] [PubMed] [Google Scholar]
  25. Sullivan V., Talarico C. L., Stanat S. C., Davis M., Coen D. M., Biron K. K. A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells. Nature. 1992 Jul 9;358(6382):162–164. doi: 10.1038/358162a0. [DOI] [PubMed] [Google Scholar]
  26. Summers J., Mason W. S. Replication of the genome of a hepatitis B--like virus by reverse transcription of an RNA intermediate. Cell. 1982 Jun;29(2):403–415. doi: 10.1016/0092-8674(82)90157-x. [DOI] [PubMed] [Google Scholar]
  27. Summers J., Smith P. M., Huang M. J., Yu M. S. Morphogenetic and regulatory effects of mutations in the envelope proteins of an avian hepadnavirus. J Virol. 1991 Mar;65(3):1310–1317. doi: 10.1128/jvi.65.3.1310-1317.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Tsiquaye K. N., Slomka M. J., Maung M. Oral famciclovir against duck hepatitis B virus replication in hepatic and nonhepatic tissues of ducklings infected in ovo. J Med Virol. 1994 Mar;42(3):306–310. doi: 10.1002/jmv.1890420319. [DOI] [PubMed] [Google Scholar]
  29. Tuttleman J. S., Pourcel C., Summers J. Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells. Cell. 1986 Nov 7;47(3):451–460. doi: 10.1016/0092-8674(86)90602-1. [DOI] [PubMed] [Google Scholar]
  30. Wang Y., Luscombe C., Bowden S., Shaw T., Locarnini S. Inhibition of duck hepatitis B virus DNA replication by antiviral chemotherapy with ganciclovir-nalidixic acid. Antimicrob Agents Chemother. 1995 Feb;39(2):556–558. doi: 10.1128/aac.39.2.556. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Yokosuka O., Omata M., Imazeki F., Okuda K., Summers J. Changes of hepatitis B virus DNA in liver and serum caused by recombinant leukocyte interferon treatment: analysis of intrahepatic replicative hepatitis B virus DNA. Hepatology. 1985 Sep-Oct;5(5):728–734. doi: 10.1002/hep.1840050505. [DOI] [PubMed] [Google Scholar]
  32. Zoulim F., Seeger C. Reverse transcription in hepatitis B viruses is primed by a tyrosine residue of the polymerase. J Virol. 1994 Jan;68(1):6–13. doi: 10.1128/jvi.68.1.6-13.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES